NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), the world leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the current therapeutic landscape and unmet medical needs for patients with chronic low back pain (CLBP) due to degenerative disc disease, a condition associated with local inflammation of the disc. The webinar will include presentations from Key Opinion Leaders (KOLs) Douglas P. Beall, MD, FIPP, FSIR, DAAPM (Clinical Radiology Oklahoma) and Hyun W. Bae, MD (Spine-Center at Cedars-Sinai Medical Center).
Mesoblast CEO Silviu Itescu will present an overview of three-year results from the completed 404-patient randomized controlled Phase 3 trial of rexlemestrocel-L in patients with CLBP due to degenerative disc disease and the regulatory route to market.
The webinar will begin at 6:00 p.m. EDT, Thursday, June 16; 8:00 a.m. AEST, Friday, June 17, 2022. Registration will be required in advance for the webcast, to access it click here or use the following link: https://lifesci.rampard.com/WebcastingAppv5/Events/eventsDispatcher.jsp ?Y2lk =MTg2OA==
The archived webcast will be available on the Investors page of the Company’s website: www.mesoblast.com
Douglas P. Beall, MD, FIPP, FSIR, DAAPM
Douglas P. Beall, MD, FIPP, FSIR, DAAPM attended medical school at Georgetown University School of Medicine in Washington, DC, and completed his residency at Johns Hopkins Hospital in Baltimore, Maryland. After residency, he served as Chief of Response Services at Sheppard Air Force Base in Wichita Falls, Texas. He then completed a fellowship in musculoskeletal radiology at the Mayo Clinic in Rochester, Minnesota, where he was trained in interventional spine techniques before returning to the US Air Force as division chief of musculoskeletal radiology. After his service as a major in the U.S. Air Force, Dr. Beall served as chief of musculoskeletal radiology and director of fellowship at the University of Oklahoma before entering private practice as chief of services . In addition to his expertise in musculoskeletal imaging and interventional spine care, Dr. Beall is actively involved in teaching and research. He is board certified in diagnostic radiology, has an additional fellowship in musculoskeletal radiology, is a graduate of the American Academy of Pain Management, and is a member of the Society of Interventional Radiology and Interventional Pain Practice and board certified by the World Pain Institute. He is currently in private practice focusing on interventional pain management and orthopedic imaging.
Dr. Beall has published over 250 articles in peer-reviewed journals, authored 6 textbooks and 75 textbook chapters, given over 1000 guest lectures and scientific presentations, and participated in 55 clinical research trials. He is currently Chief of Services for Comprehensive Specialty Care in Oklahoma City as well as Division Chief of Interventional Spine Care and Director of Pain Management Fellowship Programs at the Spine Fracture Institute and Comprehensive Care Surgical Center.
Hyun W. Bae, MD
Hyun W. Bae, MD is a board-certified orthopedic and spine surgeon. Dr. Bae joined the Spine-Center at Cedars-Sinai Medical Center in 2010. He is currently Professor of Surgery in the Department of Orthopedic Surgery at Cedars-Sinai Medical Center, Director of the Education and Fellowship Program.
Dr. Bae began his medical studies at Columbia University School of Engineering and Applied Sciences where he earned a degree in biomechanics. He then earned his medical degree, cum laude, from Yale University School of Medicine. Dr. Bae completed his surgical residency at North Shore University Hospital and his orthopedic surgery residency at the Hospital for Special Surgery in New York. He completed his Spine Fellowship at Case Western Hospital in Cleveland under the mentorship of the late Henry H. Bohlman, MD.
During 1993-1994 he conducted research in Molecular and Cellular Biology, NIH Howard Hughes Research Fellow Bethesda, MD. It was during this time that he developed a passion for musculoskeletal tissue engineering while working with scientists Guilak F, Setton LA, Soslowsky LJ, as an undergraduate student in Dr. Van Mow’s Cartilage Research Lab.
About the mesoblast
Mesoblast is a world leader in the development of allogeneic (ready-to-use) cellular drugs for the treatment of serious and life-threatening inflammatory diseases. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates that respond to severe inflammation by releasing anti-inflammatory factors that counteract and modulate multiple effector arms of the immune system, leading to a significant reduction in the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual property portfolio with protection extending to at least 2041 in all major markets. The company’s proprietary manufacturing processes produce industrial-scale, cryopreserved, ready-to-use cellular drugs. These cell therapies, with defined pharmaceutical release criteria, should be readily available to patients worldwide.
Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults, including steroid-refractory acute graft-versus-host disease, bioresistant inflammatory bowel disease and acute respiratory distress syndrome. Rexlemestrocel-L is being developed for advanced chronic heart failure and chronic low back pain. Two products have been marketed in Japan and Europe by Mesoblast licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has offices in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and Nasdaq (MESO). For more information, please visit www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
This press release contains forward-looking statements relating to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that could cause our results, levels of activity, performance or actual achievements differ materially from any future results. , the levels of activity, performance or achievements expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be construed as guarantees of future performance or results, and actual results may differ from the results anticipated in such forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements regarding: the initiation, timing, progress and results of preclinical and clinical studies of Mesoblast, as well as Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates, enroll in and complete clinical studies, including multinational clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals (including resubmission BLA), manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem cell therapies; the possibility that Mesoblast’s product candidates, if approved, may be withdrawn from the market due to adverse events or patient deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property in its product candidates and Mesoblast’s ability to successfully defend against alleged infringement; the scope of protection that Mesoblast is able to establish and maintain for the intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and additional financing requirements; the financial performance of Mesoblast; developments regarding Mesoblast’s competitors and industry; and pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release, together with our risk factors, in our latest reports filed with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those that may be expressed or implied by such statements, and accordingly, you should not place undue reliance on such forward-looking statements . We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the general manager.
For more information please contact: